Myriad
ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making
Premium
The framework, which ranks de-intensification biomarkers by evidence tiers, could give oncologists, patients, regulators, and payors a common system to guide their use.
Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing
Premium
Merck and AstraZeneca's PARP inhibitor led to a survival benefit in early-stage BRCA-mutated breast cancer, potentially necessitating broader early germline testing.
The company is offering combined germline and somatic cancer testing, and sharing patients' variants identified through that testing in a new research registry.
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.
Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch
Premium
At ASCO, the company detailed its efforts to make the 93-SNP riskScore, which it plans to offer as a standalone DTC test next year, relevant for women of all ancestries.